SKYSCRAPER-01 trial for tiragolumab and atezolizumab in NSCLC showed numerical improvements but failed to meet primary endpoints for survival. Experts argue that TIGIT remains a promising target, with ...
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. A few years back, TIGIT was hailed as the ...
Roche’s SKYSCRAPER-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to Roche's approved checkpoint inhibitor had no effect on overall survival (OS) in non-small cell ...
Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to fight cancer, potentially paving the way for new treatments. Subscribe to ...
Researchers from Instituto de Investigación Sanitaria Hospital Universitario de La Princesa and collaborators have developed nanoparticles loaded with poly(I:C) and used them to prime monocyte-derived ...
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease Apparently, nothing was wrong ...
Dendritic cells (DCs) are among the first immune sentinels to detect viruses, bacteria, or other challenges. These specialized messengers alert T cells while orchestrating either a measured calm or a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results